A final flop signals the bitter end to Circassia’s big plans for allergy R&D
Remember the big plans Circassia {LSE: CIR} had for its allergy drug pipeline when it went public, raising $333 million in 2014 with promises of big things to come for investors?
It didn’t work out. In fact, it was a complete bust.
Their Phase IIb has now wrapped for a house dust mite allergy remedy, and it failed like the rest of the studies. So Oxford, UK-based Circassia is packing it in, and switching over to a rescue strategy presented by AstraZeneca.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
